全文获取类型
收费全文 | 1758篇 |
免费 | 105篇 |
国内免费 | 113篇 |
专业分类
儿科学 | 145篇 |
妇产科学 | 28篇 |
基础医学 | 188篇 |
口腔科学 | 48篇 |
临床医学 | 214篇 |
内科学 | 426篇 |
皮肤病学 | 44篇 |
神经病学 | 71篇 |
特种医学 | 365篇 |
外国民族医学 | 1篇 |
外科学 | 88篇 |
综合类 | 43篇 |
一般理论 | 3篇 |
预防医学 | 86篇 |
眼科学 | 17篇 |
药学 | 103篇 |
中国医学 | 2篇 |
肿瘤学 | 104篇 |
出版年
2023年 | 5篇 |
2022年 | 8篇 |
2021年 | 20篇 |
2020年 | 16篇 |
2019年 | 14篇 |
2018年 | 28篇 |
2017年 | 9篇 |
2016年 | 35篇 |
2015年 | 38篇 |
2014年 | 29篇 |
2013年 | 55篇 |
2012年 | 74篇 |
2011年 | 66篇 |
2010年 | 75篇 |
2009年 | 60篇 |
2008年 | 36篇 |
2007年 | 86篇 |
2006年 | 48篇 |
2005年 | 69篇 |
2004年 | 30篇 |
2003年 | 26篇 |
2002年 | 16篇 |
2001年 | 24篇 |
2000年 | 26篇 |
1999年 | 30篇 |
1998年 | 92篇 |
1997年 | 96篇 |
1996年 | 106篇 |
1995年 | 66篇 |
1994年 | 63篇 |
1993年 | 67篇 |
1992年 | 18篇 |
1991年 | 40篇 |
1990年 | 32篇 |
1989年 | 55篇 |
1988年 | 42篇 |
1987年 | 60篇 |
1986年 | 33篇 |
1985年 | 51篇 |
1984年 | 24篇 |
1983年 | 16篇 |
1982年 | 26篇 |
1981年 | 23篇 |
1980年 | 31篇 |
1979年 | 14篇 |
1978年 | 22篇 |
1977年 | 17篇 |
1976年 | 28篇 |
1975年 | 16篇 |
1972年 | 3篇 |
排序方式: 共有1976条查询结果,搜索用时 15 毫秒
51.
Paula Finnegan John Jefferies Ronan Margey Barry Hennigan 《The British Journal of Cardiology》2020,27(4)
We provide the details of three cases utilising intravascular lithotripsy, a novel approach to percutaneous coronary intervention (PCI).Key words: calcific stenosis, intravascular lithotripsy, shockwave, stents 相似文献
52.
Muddassir Mehmood Stephanie A. Ambach Michael D. Taylor John L. Jefferies Subha V. Raman Robin J. Taylor Hemant Sawani Jacob Mathew Wojciech Mazur Kan N. Hor Hussein R. Al-Khalidi 《Pediatric cardiology》2016,37(5):878-883
The relationship between pulmonary function and right ventricle (RV) in Duchenne muscular dystrophy (DMD) has not been evaluated. Using cardiac magnetic resonance (CMR), we describe the relationship of RV size and function with spirometry in a DMD cohort. Fifty-seven boys undergoing CMR and pulmonary function testing within 1 month at a single center (2013–2015) were enrolled. Comparisons of RV ejection fraction (RVEF) and end-diastolic volume index (RVEDVI) were made across categories of percent forced vital capacity (FVC%), and relationships were assessed. Mean age was 15.5 ± 3.5 years. Spirometry and CMR were performed within 3.9 ± 4.1 days. Median FVC% was 92.0 % (67.5–116.5 %). Twenty-three (40 %) patients had abnormal FVC% (<80 %) of which 13 (57 %) had mild (FVC% 60–79 %), 6 (26 %) had moderate (FVC% 40–59 %), and 4 (17 %) had severe (FVC <40 %) reductions. Mean RVEF was 58.3 ± 3.7 %. Patients with abnormal FVC% were older and had lower RVEF and RVEDVI. Both RVEF and RVEDVI were significantly associated with FVC% (r = 0.31, p = 0.02 and r = 0.39, p = 0.003, respectively). In a large DMD cohort, RVEF and RVEDVI were related to FVC%. Worsening respiratory status may guide monitoring of cardiac function in these patients. 相似文献
53.
Deipanjan Nandi Kimberly Y. Lin Matthew J. O’Connor Okan U. Elci Jeffrey J. Kim Jamie A. Decker Jack F. Price Farhan Zafar David L. S. Morales Susan W. Denfield William J. Dreyer John L. Jefferies Joseph W. Rossano 《Pediatric cardiology》2016,37(3):512-518
Scarce data exist regarding costs of pediatric heart failure-related hospitalizations (HFRH) or how costs have changed over time. Pediatric HFRH costs, due to advances in management, will have increased significantly over time. A retrospective analysis of Healthcare Cost and Utilization Project Kids’ Inpatient Database was performed on all pediatric HFRH. Inflation-adjusted charges are used as a proxy for cost. There were a total of 33,189 HFRH captured from 2000 to 2009. Median charges per HFRH rose from $35,079 in 2000 to $72,087 in 2009 (p < 0.0001). The greatest median charges were incurred in patients on extracorporeal membrane oxygenation ($442,134 vs $53,998) or ventricular assist devices ($462,647 vs $55,151). Comorbidities, including sepsis ($207,511 vs $48,995), renal failure ($180,624 vs $52,812), stroke ($198,260 vs $54,974) and respiratory failure ($146,200 vs $48,797), were associated with greater charges (p < 0.0001). Comorbidities and use of mechanical support increased over time. After adjusting for these factors, later year remained associated with greater median charges per HFRH (p < 0.0001). From 2000 to 2009, there has been an almost twofold increase in pediatric HFRH charges, after adjustment for inflation. Although comorbidities and use of mechanical support account for some of this increase, later year remained independently associated with greater charges. Further study is needed to understand potential factors driving these higher costs over time and to identify more cost-effective therapies in this population. 相似文献
54.
55.
JL Adams M Murray N Patel MT Sawkin RC Boardman C Pham H Kaur D Patel JL Yager L Pontiggia J Baxter 《HIV medicine》2021,22(1):28-36
56.
巨噬细胞迁移抑制因子最初是由于能抑制体外巨噬细胞随机迁移而被发现,现在它作为一种重要的调节因子参与一系列炎症性疾病过程.我们最近发现,巨噬细胞迁移抑制因子的缺失使一些由炎症介质诱发的白细胞-内皮细胞相互作用减弱,提示巨噬细胞迁移抑制因子在炎症反应中起作用的机制之一是促进白细胞聚集.…… 相似文献
57.
Michon J; Moutel S; Barbet J; Romet-Lemonne JL; Deo YM; Fridman WH; Teillaud JL 《Blood》1995,86(3):1124-1130
Neutrophils isolated from cancer patients treated with granulocyte colony-stimulating factor (G-CSF) express high levels of Fc gamma RI. They exhibited an efficient killing of GD2+ neuroblastoma cells in the presence of an antidisialoganglioside (GD2) mouse monoclonal antibody (MoAb; 7A4, IgG3 kappa). However, this cytotoxicity was totally blocked by human monomeric IgG. In contrast, a bispecific antibody (7A4 bis 22/MDX-260), prepared by chemically linking an F(ab') fragment of 7A4 with an F(ab') fragment of an anti-Fc gamma RI MoAb, 22, which binds outside the Fc binding domain, triggered antibody-dependent cell cytotoxicity, even when neutrophils were preincubated with human monomeric IgG. F(ab')2 22 MoAb abrogated the MDX-260 killing without affecting that of 7A4. The 3G8 MoAb, directed against the Fc gamma RIII binding site, did not inhibit the cytotoxicity induced by either antibody. Thus, these results indicate that G-CSF-activated neutrophils exert their cytotoxic effect against neuroblastoma cells through Fc gamma RI and not Fc gamma RIII, and that the saturation of the high affinity Fc gamma RI by monomeric IgG can be overcome by the use of bispecific antibodies binding epitopes outside the IgG Fc gamma RI binding site. A combined administration of such bispecific antibodies and G-CSF may be, therefore, an efficient therapeutic approach to trigger tumor lysis by cytotoxic neutrophils in vivo. 相似文献
58.
59.
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia 总被引:5,自引:2,他引:5
Beran M; Kantarjian H; O'Brien S; Koller C; al-Bitar M; Arbuck S; Pierce S; Moore M; Abbruzzese JL; Andreeff M; Keating M; Estey E 《Blood》1996,88(7):2473-2479
The aim of this study was to evaluate the activity of topotecan in patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Forty-seven patients with a diagnosis of MDS (n = 22) or CMML (n = 25) were treated. The median age was 66 years. Chromosomal abnormalities were present in 70% and thrombocytopenia less than 50 x 10(3)/microL in 51%. Evaluation of outcome and of differences among subgroups was performed according to standard methods; the criteria for response were those used for acute leukemia. Topotecan was administered as 2 mg/ m2 by continuous infusion over 24 hours daily for 5 days (10 mg/m2 per course) every 3 to 4 weeks until remission, then once every month for a maximum of 12 courses. Thirteen patients (28%) achieved a complete response (CR) and six (13%) had hematologic improvement. A CR was achieved in six of 22 patients with MDS (27%) and in seven of 25 with CMML (28%). All eight patients who presented with cytogenetic abnormalities (five chromosome 5 or 7 abnormalities) who achieved CR were cytogenetically normal in CR. Characteristics for which there was evidence of association with a higher response rate were lack of prior chemotherapy, less than 10% marrow monocytes, and absence of RAS oncogene mutations. In contrast, CR rates were similar in patients with or without abnormal karyotypes. Mucositis occurred in 64% of patients (severe in 19%) and diarrhea in 32% (severe in 13%). Febrile episodes occurred in 85% of patients and documented infections in 47%. With a median follow-up duration of 8 months, the 12-month survival rate was 38%, median survival time 10.5 months, and median remission duration 7.5 months. We conclude that topotecan has significant activity in MDS and CMML, with acceptable side effects. Future studies will investigate topotecan combined with topoisomerase II reactive agents, cytarabine, or hypomethylating agents (azacytidine and decitabine). 相似文献
60.
Cardoso AA; Schultze JL; Boussiotis VA; Freeman GJ; Seamon MJ; Laszlo S; Billet A; Sallan SE; Gribben JG; Nadler LM 《Blood》1996,88(1):41-48
Even if neoplastic cells express tumor associated antigens they still may fail to function as antigen presenting cells (APC) if they lack expression of one or more molecules critical for the induction of productive immunity. These cellular defects can be repaired by physiologic activation, transfection, or fusion of tumor cells with professional APC. Although such defects can be repaired, antitumor specific T cells may still fail to respond in vivo if they may have been tolerized. Here, human pre-B cell acute lymphoblastic leukemia (pre-B ALL) was used as a model to determine if primary human tumor cells can function as alloantigen presenting cells (alloAPC) or alternatively whether they induce anergy. In the present report, we show that pre-B cell ALL express alloantigen and adhesion molecules but uniformly lack B7-1 (CD80) and only a subset express B7-2 (CD86). Pre-B ALL cells are inefficient or ineffective alloAPC and those cases that lack expression of B7-1 and B7-2 also induce alloantigen specific T- cell unresponsiveness. Under these circumstances, T-cell unresponsiveness could be prevented by physiologic activation of tumor cells via CD40, cross-linking CD28, or signaling through the common gamma chain of the interleukin-2 receptor on T cells. Taken together, these results suggest that pre-B ALL may be incapable of inducing clinically significant T-cell-mediated antileukemia responses. This defect may be not only due to their inability to function as APC, but also due to their potential to induce tolerance. Attempts to induce clinically significant antitumor immune responses may then require not only mechanisms to repair the antigen presenting capacity of the tumor cells, but also reversal of tolerance. 相似文献